Can Eli Lilly Stock Rebound After A 10% Drop Over Alzheimer’s Drug?

The stock price of Eli Lilly & Company has seen a 10% drop over the last five trading days, after the company announced mixed results from clinical trials of Donanemab, a drug for the treatment of Alzheimer’s disease. While the drug met the primary endpoint, it failed to meet a more important...